Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed.

In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine.

Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good.

Read full article

Comments

Nearly a month into the Ebola outbreak in the Democratic Republic of the Congo, cases continue to rise as officials are still trailing the virus in their response efforts.

As of Thursday, June 11, the DRC has reported 676 confirmed cases, 136 deaths, and 119 suspected cases. Uganda is reporting 19 confirmed cases and two deaths.

The outbreak, caused by the Bundibugyo strain of Ebolavirus, is already the third largest Ebola outbreak on record. But health experts fear that it could grow much larger and had been quietly spreading for months before the outbreak was declared on May 15.

Read full article

Comments